GENEOSCOPY INC.


Associated tags: Disease, RNA, Colorectal cancer, Vaccine, CRC, Patient, MBA, Pharmaceutical industry, Medicine, Gastrointestinal disease, Health, Food, GI, FDA, Genetics, Inflammatory bowel disease, Diagnosis, PMA, Serna, IBD, Biotechnology

Locations: NEW YORK, NY, JAMA, UNITED STATES, NORTH AMERICA, MISSOURI, US

Geneoscopy Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

Retrieved on: 
Tuesday, November 14, 2023
Men, Pharmaceutical, Oncology, Consumer, Medical Devices, Genetics, Science, Biotechnology, Women, Medical Supplies, Seniors, Health, Other Science, Research, NYSE, Incidence, Colorectal cancer, CRC, Collection, Mortality, Patient, Conditional sentence, FDA, LH, Cancer, PMA, RNA, Pharmaceutical industry, Labcorp

This multi-year agreement will increase access to Geneoscopy’s next-generation colorectal cancer screening test, which offers at-home collection and high sensitivity for early cancer detection.

Key Points: 
  • This multi-year agreement will increase access to Geneoscopy’s next-generation colorectal cancer screening test, which offers at-home collection and high sensitivity for early cancer detection.
  • Geneoscopy’s technology offers this age group convenient at-home test collection with the highest sensitivity currently available for non-invasive CRC screening.
  • “Geneoscopy’s highly sensitive colorectal cancer screening test, once approved, will be another innovative, accessible and reliable option available to providers and patients nationwide for the detection of colorectal cancer.”
    Geneoscopy’s multi-target stool RNA (mt-sRNA) biomarker panel is designed to detect precancerous lesions and colorectal cancer.
  • These results are the highest reported for any noninvasive CRC screening test in any prospective registrational clinical study completed to date.

JAMA Publishes Geneoscopy’s Pivotal CRC-PREVENT Trial Results, Reporting Highest Sensitivity for Detecting Colorectal Cancer and Advanced Adenomas Among Available Noninvasive Screening Tests

Retrieved on: 
Monday, October 23, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Medical Devices, GI, FDA, American College, AA, Incidence, Multi, JD, RNA, Oregon Health & Science University, ACG, American Medical Association, Colorectal cancer, Medicine, Doctor of Philosophy, MBA, PMA, American College of Gastroenterology, Journal, Inflammatory bowel disease, CRC, AAS, IBD, USPSTF, Cancer, Ponce Health Sciences University, Patient, Gastrointestinal disease, Pharmaceutical industry, Vaccine, MD

The novel study will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Vancouver, Canada, October 20-25, showcasing its highly sensitive screening test for colorectal cancer (CRC) and advanced adenomas (AA).

Key Points: 
  • The novel study will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Vancouver, Canada, October 20-25, showcasing its highly sensitive screening test for colorectal cancer (CRC) and advanced adenomas (AA).
  • “Geneoscopy is dedicated to addressing this challenge and improving access to a reliable, noninvasive CRC screening test, especially as incidence is rising among younger populations.
  • Notably, for younger participants (ages 45 to 49), CRC sensitivity was 100% and AA sensitivity was 45%.
  • There is a notable gap in data regarding the efficacy of noninvasive screening tests for this age group, including the sensitivity for colorectal cancer (CRC) and advanced adenomas,” said Dr. Lieberman.

Geneoscopy to Present and Exhibit at American College of Gastroenterology 2023 Annual Meeting

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, Health, Other Health, Oncology, Other Science, Research, Medical Devices, Managed Care, Infectious Diseases, Hospitals, Genetics, Science, Nursing, Medical Supplies, GI, Incidence, Medicine, Food, American College of Gastroenterology, American College, RNA, Physician, IBD, CRC, Patient, FDA, Colorectal cancer, ACG, Inflammatory bowel disease, Gastrointestinal disease, Medical device, Medical imaging

Despite declining incidence in the overall population, CRC is increasing amongst individuals under 55 and shifting to a more advanced disease.

Key Points: 
  • Despite declining incidence in the overall population, CRC is increasing amongst individuals under 55 and shifting to a more advanced disease.
  • Geneoscopy is leveraging its novel RNA-based technology platform to address these challenges to develop noninvasive diagnostic and precision medicine tools for GI diseases.
  • “Geneoscopy is focused on providing innovative screening and diagnostic tests to help empower patients and providers to transform gastrointestinal health,” said Andrew Barnell, CEO of Geneoscopy.
  • We want to meet patients where they are with accessible, convenient, and highly accurate tools that fit into their busy lives.”

Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 6, 2023
General Health, Genetics, Health, Gastrointestinal disease, CRC, IBD, MBA, Research, RNA, Inflammatory bowel disease, Incidence, PMA, Patient, Colorectal cancer, Medicine, Morgan, FDA, GI, Conference, Food, Pharmaceutical industry

Geneoscopy Inc. , a life sciences company focused on developing diagnostic tests for gastrointestinal health, today announced that Chief Executive Officer and Co-founder Andrew Barnell, MBA, will be presenting at the Morgan Stanley Global Healthcare Conference in New York, NY, on Monday, Sept. 11, at 2:15 p.m. Eastern Time.

Key Points: 
  • Geneoscopy Inc. , a life sciences company focused on developing diagnostic tests for gastrointestinal health, today announced that Chief Executive Officer and Co-founder Andrew Barnell, MBA, will be presenting at the Morgan Stanley Global Healthcare Conference in New York, NY, on Monday, Sept. 11, at 2:15 p.m. Eastern Time.
  • In addition, a recent study found that nearly 1 in 100 Americans suffer from IBD, with an estimated 2.39 million diagnosed.
  • “We are pleased to be presenting at Morgan Stanley’s Annual Global Healthcare Conference to share the promising market opportunities for our proprietary RNA biomarker platform and high-value diagnostic tests,” said Andrew Barnell, CEO and Co-founder of Geneoscopy.
  • These results are the highest reported for any noninvasive CRC screening test in any prospective registrational clinical study completed to date.

Geneoscopy appoints Don Hardison to its Board of Directors

Retrieved on: 
Tuesday, February 28, 2023
Genetics, Biotechnology, Exact sciences, Hologic, Colorectal cancer, Acquisition, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, PMA, CRC, Labcorp, Food, Management, Pharmaceutical industry

ST. LOUIS, Feb. 28, 2023 /PRNewswire/ -- Geneoscopy, a developer of innovative diagnostics for gastrointestinal health, announced the appointment of Don Hardison to its board of directors.

Key Points: 
  • ST. LOUIS, Feb. 28, 2023 /PRNewswire/ -- Geneoscopy, a developer of innovative diagnostics for gastrointestinal health, announced the appointment of Don Hardison to its board of directors.
  • Mr. Hardison joins Geneoscopy 's Board of Directors with over 40 years of executive leadership experience in emerging and Fortune 500 diagnostics, biotechnology and life sciences companies.
  • Mr. Hardison served as president and CEO of Biotheranostics until its acquisition by Hologic in February 2021.
  • I am pleased to join Geneoscopy's board at such an exciting time for the company, " said Mr. Hardison.

Geneoscopy's Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial

Retrieved on: 
Tuesday, January 10, 2023
Cancer, AA, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biomarker, Division, Risk, Colorectal cancer, Trial of the century, Sale, Patient, CRC, Degenerative disease, American Gastroenterological Association, FDA, Hepatology, Endoscopy, Diagnosis, Collection, RNA, Medical imaging, Pharmaceutical industry, Medical device, Gastroenterology

ST. LOUIS, Jan. 10, 2023 /PRNewswire/ -- Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced favorable results from the CRC-PREVENT trial – a pivotal clinical trial evaluating the efficacy of its noninvasive, stool-based, at-home diagnostic screening test to detect colorectal cancer (CRC) and advanced adenomas (AA) in average-risk individuals. In the trial, Geneoscopy's stool-based screening test met the clinical endpoints across all primary outcome measures, including sensitivity and specificity for CRC and AA.

Key Points: 
  • In the trial, Geneoscopy's stool-based screening test met the clinical endpoints across all primary outcome measures, including sensitivity and specificity for CRC and AA.
  • "...Our test may allow patients to get appropriate treatment, in some cases, even before cancer develops."
  • Efficacy results from the study include:
    These sensitivity results are the highest reported for any noninvasive CRC screening test in any prospective registrational clinical study completed to date.
  • The large-scale prospective clinical study data demonstrate that this noninvasive CRC screening test can accurately detect if people have cancer and if they have advanced adenomas that put them at higher risk of developing cancer.

Geneoscopy Announces Formation of Scientific Advisory Board to Inform Strategy for the Advancement of Gastrointestinal Health

Retrieved on: 
Tuesday, June 21, 2022
Digestive, Internal medicine, MACP, RNA, Department, Stanford University School of Medicine, Department of Human Services and Health, MBA, University of Michigan, GI, University School, Technology, National Institute of Diabetes and Digestive and Kidney Diseases, Head, Gastrointestinal cancer, Population health, Nuffield Department of Population Health, Survival, Company, Coronavirus Scientific Advisory Board (Turkey), Genetics, Colorectal cancer, Division, Statistics, Hepatology, Serna, Disease, Large intestine, FACS, Kidney, University, Department of Medicine – University of Pamplona, SAB, Health, Patient, Board, MPH, Diagnosis, Gastrointestinal disease, NIH, New York University Grossman School of Medicine, Medical device, Management, Fast food, Pharmaceutical industry, Medicine, Gastroenterology

ST. LOUIS, June 21, 2022 /PRNewswire/ -- Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in gastroenterology, oncology, and internal medicine. The SAB will provide strategic input based on their scientific knowledge and clinical expertise to help guide Geneoscopy through the development, regulatory and commercial phases for their RNA-based technology to improve GI health, starting with colorectal cancer.

Key Points: 
  • John Carethers, M.D., MACP Professor and Chair, Department of Internal Medicine and Professor, Department of Human Genetics at University of Michigan
    Uri Ladabaum, M.D.
  • The advancement of new technologies is critical for the early detection, diagnosis and potentially even prevention of these illnesses," noted Board member David Lieberman, M.D.
  • "The establishment of our Scientific Advisory Board is a significant step forward in our mission to transform GI health.
  • Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health.

Geneoscopy Appoints Dr. Haytham Gareer as Chief Medical Officer

Retrieved on: 
Monday, October 18, 2021
View, Technology, MBA, Olympus, National Cancer Institute, Thomas Jefferson University, Master, Cancer, Haitham, Disease, Multimedia, RNA, Serna, Colorectal cancer, Medicine, Company, Hult International Business School, University, US, Olympus Corporation, CRC, Cairo University, Surgical oncology, Surgery, COVID-19, Medical imaging

ST. LOUIS, Mo., Oct. 18, 2021 /PRNewswire/ -- Geneoscopy Inc. , a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced it has named Haytham Gareer, MD, Ph.D. to serve as the company's Chief Medical Officer.

Key Points: 
  • ST. LOUIS, Mo., Oct. 18, 2021 /PRNewswire/ -- Geneoscopy Inc. , a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced it has named Haytham Gareer, MD, Ph.D. to serve as the company's Chief Medical Officer.
  • A trained surgical oncologist, Dr. Gareer brings two decades of medical and clinical affairs experience and will serve a critical role in Geneoscopy's efforts to launch its non-invasive, RNA-FIT colorectal cancer screening test.
  • "The COVID-19 pandemic has highlighted the importance of test sensitivity, as well as providing a means for convenient, at-home screening options, especially for cancer," commented Dr. Gareer.
  • He is a proven medical affairs leader with an impressive track record developing and executing successful clinical strategies, with key gastrointestinal clinical expertise," commented Andrew Barnell, Geneoscopy's co-founder and Chief Executive Officer.

Geneoscopy Honored by Goldman Sachs for Entrepreneurship

Retrieved on: 
Wednesday, October 13, 2021
GS, Goldman Sachs, View, MBA, Diagnosis, Entrepreneurship, Jane Barnell, World Innovation Summit for Health, Economics, Lindsay Goldberg, Charles H. Dyson School of Applied Economics and Management, BA, Builder, J.P. Morgan & Co., Disease, NYSE, Specialization, Multimedia, RNA, Serna, Colorectal cancer, Company, Wharton School of the University of Pennsylvania, J. P. Morgan, CEO, Innovation, US, Cornell University, Management

Goldman Sachs selected Barnell as one of 100 entrepreneurs from multiple industries to be honored at the two-day event.

Key Points: 
  • Goldman Sachs selected Barnell as one of 100 entrepreneurs from multiple industries to be honored at the two-day event.
  • Prior to co-founding Geneoscopy, he was an associate at Lindsay Goldberg, a middle-market private equity firm focused on partnering with family-owned businesses.
  • "We are honored to have Andrew recognized as part of this distinguished group of entrepreneurs," commented Vince Wong, Geneoscopy's Chief Commercial Officer.
  • "Innovation doesn't happen just anywhere; it thrives where there's a wide range of thoughts and perspectives," said David M. Solomon, Chairman & CEO of Goldman Sachs.

Geneoscopy Announces Publication of Peer-Reviewed Article Highlighting Effective Noninvasive Screening Test for Colorectal Cancer Prevention

Retrieved on: 
Tuesday, May 25, 2021
General Health, Medical devices, Other Health, Health, Oncology, Medicine, Clinical medicine, Health, Colorectal cancer, Cancer screening, Screening, Cancer

Geneoscopy Inc. today announced publication of the peer-reviewed article, Multitarget Stool RNA Test for Noninvasive Detection of Colorectal Neoplasias in a Multicenter, Prospective, and Retrospective Cohort, which presents the results of its multifactor RNA-FIT test in Clinical and Translational Gastroenterology.

Key Points: 
  • Geneoscopy Inc. today announced publication of the peer-reviewed article, Multitarget Stool RNA Test for Noninvasive Detection of Colorectal Neoplasias in a Multicenter, Prospective, and Retrospective Cohort, which presents the results of its multifactor RNA-FIT test in Clinical and Translational Gastroenterology.
  • The article reports high sensitivity of the companys noninvasive, at-home diagnostic screening test to successfully detect colorectal neoplasms, including advanced adenomas, in average-risk individuals within the intended use population for colorectal cancer screening.
  • Geneoscopys lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas.
  • The information contained in this release includes information about Geneoscopys future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, and as such constitute forward-looking statements.